Poisoning from delayed release tablets.
نویسندگان
چکیده
منابع مشابه
Poisoning with delayed-release tablets. Treatment of Debendox poisoning with purgation and dialysis.
Meadow, S. R., and Leeson, G. A. (1974). Archives of Disease in Childhood, 49, 310. Poisoning with delayed-release tablets: treatment of Debendox poisoning with purgation and dialysis. Accidental poisoning with delayedrelease tablets causes symptoms at a time when the tablets can no longer be retrieved from the stomach. A child died from eating 23 tablets of Debendox, which is a delayed-release...
متن کاملDEPAKOTE® Tablets DIVALPROEX SODIUM DELAYED-RELEASE TABLETS
BOX WARNING: HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED IN PATIENTS RECEIVING VALPROIC ACID AND ITS DERIVATIVES. EXPERIENCE HAS INDICATED THAT CHILDREN UNDER THE AGE OF TWO YEARS ARE AT A CONSIDERABLY INCREASED RISK OF DEVELOPING FATAL HEPATOTOXICITY, ESPECIALLY THOSE ON MULTIPLE ANTICONVULSANTS, THOSE WITH CONGENITAL METABOLIC DISORDERS, THOSE WITH SEVERE SEIZURE DISORDERS ACCOMPANIE...
متن کاملPREVACID (lansoprazole) Delayed-Release Capsules PREVACID SoluTab (lansoprazole) Delayed-Release Orally Disintegrating Tablets For oral administration
-----------------------------DRUG INTERACTIONS-------------------------- • Atazanavir: Do not co-administer with atazanavir. (7.1) • Drugs with pH-Dependent Absorption: May interfere with the absorption of drugs where gastric pH is important for bioavailability. (7.1) • Warfarin: Concomitant warfarin use may require monitoring for increases in INR and prothrombin time. (7.2) • Tacrolimus: Conc...
متن کاملPROTONIX®(pantoprazole sodium)Delayed-Release Tablets PROTONIX ®(pantoprazole sodium)For Delayed-Release Oral Suspension
DESCRIPTION The active ingredient in PROTONIX (pantoprazole sodium) Delayed-Release Tablets and PROTONIX (pantoprazole sodium) For Delayed-Release Oral Suspension is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]1H-benzimidazole sesquihydrate, a compound that inhibits gastric acid secretion. Its empirical formula is C16H14F2N3NaO4S x 1.5...
متن کاملBioavailability and stability of erythromycin delayed release tablets.
BACKGROUND Erythromycin is available as the free base, ethylsuccinate, estolate, stearate, gluceptate, and lactobionate derivatives. When given orally erythromycin and its derivatives except the estolate are inactivated to some extent by the gastric acid and poor absorption may result. OBJECTIVES To establish whether delayed release erythromycin tablets meet the bioequivalent requirement for ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1972
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.1.5798.512-a